Softwr

Healthcare · head to head

PathAI vs Sysmex

PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite
Sysmex logo

Sysmex

Healthcare

Haematology and urinalysis analysers sold with the middleware that decides which results a scientist ever sees

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.; Sysmex the middleware is not realistically separable from the instrument contract, so a laboratory that likes Caresphere but wants another vendor analyser has no clean path to buying just the software.
  • They diverge on capability: PathAI covers AISight image management, Sysmex covers Caresphere autovalidation.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which PathAI and Sysmex actually diverge.

Attributes where PathAI and Sysmex differ
AttributePathAISysmex
PlatformsWebWeb, Windows, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

Only in Sysmex

  • Caresphere autovalidation
  • Delta and moving average QC
  • WAM rule sets
  • Fleet telemetry
  • Reagent inventory tracking
  • Extended white cell parameters
  • LIS interfacing
  • Multi-site harmonisation

What people use each for

The jobs each tool is most often brought in to do.

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Sysmex
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Sysmex
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Sysmex
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Sysmex

Sysmex

  • A hospital network standardising full blood count reporting across six laboratories so a result released at a district hospital carries the same rules as the tertiary centrenot PathAI
  • A pathology group trying to raise autovalidation rates to absorb rising demand without recruiting more biomedical scientistsnot PathAI
  • A blood sciences service consolidating haematology, coagulation and urinalysis onto one middleware layer to remove three separate QC workflowsnot PathAI
  • A laboratory running 24 hour service that needs remote analyser telemetry so an overnight fault is triaged before the morning shift arrivesnot PathAI

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Sysmex

  • The middleware is not realistically separable from the instrument contract, so a laboratory that likes Caresphere but wants another vendor analyser has no clean path to buying just the software.
  • Reagent rental agreements set a minimum annual test volume, and a laboratory whose activity falls after a service reconfiguration keeps paying against a floor it no longer reaches.
  • Regulatory clearance is granted per parameter and per region, so a flag or extended parameter that a European laboratory relies on may not be released for clinical use on the same analyser in the United States.
  • Interfacing to a non-Sysmex laboratory information system is a project, not a configuration step, and integration effort is often quoted separately from the instrument contract.
  • Autovalidation rule sets are configured locally, so the gains depend entirely on whether the laboratory has the clinical governance capacity to write, validate and audit those rules; buying the software does not deliver the saving on its own.

Pricing, plan by plan

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Sysmex

On request
  • Reagent rental or cost per reportable result contract$undefined/year
    • Analyser hardware, reagents, service and Caresphere middleware bundled into a price per test
    • Five to seven year term typical
    • Minimum annual test volume commitment

Which should you pick?

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Choose Sysmex if

  • You need caresphere autovalidation.
  • You work on Web, Windows, On-premise.
  • You also want delta and moving average qc.
Sysmex review

Questions people ask

Is PathAI or Sysmex better?
Neither clearly leads. PathAI starts at On request and Sysmex at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, PathAI or Sysmex?
PathAI starts at On request and Sysmex at On request.
Does PathAI or Sysmex run on more platforms?
PathAI runs on Web. Sysmex runs on Web, Windows, On-premise.
What is PathAI best used for?
PathAI is most often used for an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version, a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location, a pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readers, a laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewer. Of those, an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version and a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location are not what Sysmex is typically brought in for.
What can PathAI do that Sysmex cannot?
PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management. Sysmex covers Caresphere autovalidation, Delta and moving average QC, WAM rule sets, Fleet telemetry.

Answered from the vendors’ own pages

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Sysmex: Can I buy Caresphere without Sysmex analysers?

Not in practice. It is licensed as part of the instrument and reagent agreement, and its value depends on Sysmex-specific parameters and flags.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Sysmex: Is Sysmex software FDA cleared?

Clearance attaches to the analysers and to individual reported parameters, not to the middleware as a whole. Check the specific parameter and the specific market, because clearances differ between the United States, Europe and Japan.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Sysmex: How is it priced?

Per reportable result, or as a reagent rental with a minimum annual volume. There is no per user or per seat price.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Sysmex: What is the contract length?

Typically five to seven years, aligned to instrument depreciation, with reagent pricing fixed or indexed over the term.

Share

Related pages

More on PathAI

More on Sysmex

Keep looking

Other head to heads